

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **December 17, 2021**

BIONIK LABORATORIES CORP.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

000-54717
(Commission File Number)

27-1340346
(IRS Employer Identification No.)

80 Coolidge Hill Road
Watertown, MA
(Address of Principal Executive Offices)

02472
(Zip Code)

Registrant's Telephone Number, Including Area Code: (617) 926-4800

483 Bay Street, N105
Toronto, ON M5G 2C9
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Not applicable	Not applicable	Not applicable

Item 5.07 Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders (the "Annual Meeting") of Bionik Laboratories Corp. (the "Company") was held on December 17, 2021. At the Annual Meeting, the stockholders of the Company voted on the following four proposals and cast their votes as described below. The proposals are described in more detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on November 17, 2021.

Proposal 1: Election of the seven nominees listed below to serve on the Board of Directors of the Company until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified:

Nominee	For	Withhold Authority
Andre Auberton-Herve	3,400,063	5,091
Remi Gaston-Dreyfus	3,410,495	15,523
P. Gerald Malone	3,400,063	15,523
Joseph Martin	3,400,063	15,523
Charles Matine	3,400,063	15,523
Audrey Thevenon	3,373,967	41,619
Michal Prywata	3,403,398	12,188

Proposal 2: To approve an advisory (non-binding) resolution to approve the compensation of the Company's named executive officers.

For	Against	Abstain
-----	---------	---------

3,407,847

6,430

1,309

Proposal 3: To recommend, on an advisory (non-binding) basis, the frequency with which shareholders shall be entitled to vote on the compensation of named executive officers.

One Year	Two Years	Three Years	Abstain
59,655	666,868	2,688,178	855

Accordingly, the Company's board of directors determined that the Company will hold a say-on-pay advisory vote every three years.

Proposal 4: To ratify MNP, LLP as the Company's independent public accountants for the year ending March 31, 2022.

For	Against	Abstain
3,467,635	1,049	3,136

Item 9.01 Financial Statements and Exhibits.

<u>Exhibit</u>	<u>Description</u>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 20, 2021

BIONIK LABORATORIES CORP.

By: /s/ Rich Russo Jr.
 Name: Rich Russo Jr.
 Title: Chief Financial Officer and Interim CEO